NEW YORK (360Dx) – The market for interferon-gamma release assays (IGRAs) for detecting latent tuberculosis is growing rapidly in more industrialized areas of the world, a trend that is expected to continue in the wake of recently issued recommendations from a number of expert organizations and as peer-reviewed evidence for the tests' effectiveness mounts.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.